Meta Information
ID:phenylpiracetam
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Interactions
Target id:
/class/stimulants
Target name:
Stimulant Medications
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Phenylpiracetam has significant psychostimulant properties that add to the effects of other stimulants (e.g., amphetamines, methylphenidate), increasing the risk of overstimulation, anxiety, insomnia, and cardiovascular side effects like hypertension and tachycardia.
Actionable advice:
Co-administration with other stimulant medications should be avoided unless under strict medical supervision.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/class/maois
Target name:
Monoamine Oxidase Inhibitors (MAOIs)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Phenylpiracetam may increase dopamine levels, and co-administration with MAOIs could theoretically lead to a hypertensive crisis or serotonin syndrome due to excessive monoamine accumulation.
Actionable advice:
Phenylpiracetam should not be used with MAOIs at all.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/bipolar-disorder
Target name:
Bipolar Disorder
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The potent stimulant and dopaminergic effects of phenylpiracetam can potentially induce mania or hypomania in individuals with bipolar disorder.
Actionable advice:
Use should be avoided with bipolar disorder, especially without consulting a psychiatrist.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/psychosis-history
Target name:
History of Psychosis
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
As a dopaminergic stimulant, phenylpiracetam may exacerbate or trigger psychotic symptoms in individuals with a personal or family history of psychotic disorders.
Actionable advice:
Use should be avoided with a personal or strong family history of psychosis.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/cardiovascular-disease
Target name:
Cardiovascular Disease
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The stimulant properties of phenylpiracetam can increase blood pressure and heart rate, which may pose a significant risk for individuals with pre-existing cardiovascular conditions like hypertension, arrhythmias, or coronary artery disease.
Actionable advice:
Use should be avoided with a history of significant cardiovascular disease or uncontrolled hypertension.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The safety of phenylpiracetam during pregnancy has not been established, and its use is contraindicated due to unknown risks to fetal development.
Actionable advice:
This should be strictly avoided during pregnancy.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is unknown if phenylpiracetam is excreted in breast milk, and its stimulant properties could be harmful to a nursing infant.
Actionable advice:
This should be strictly avoided while breastfeeding.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
8
Hours after target:
null
Description:
Phenylpiracetam is a potent psychostimulant with a half-life of 3-5 hours that can significantly delay sleep onset, reduce sleep quality, and cause insomnia if taken too close to bedtime.
Actionable advice:
A dose should be taken in the morning and should not be taken within 8 hours of the planned bedtime.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
separate
Target id:
/intervention/caffeine
Target name:
Caffeine
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The stimulant effects of phenylpiracetam can be potentiated by caffeine, leading to an increased risk of jitteriness, anxiety, heart palpitations, and insomnia.
Actionable advice:
Caution is warranted, and reducing or eliminating caffeine intake is worth considering, when using phenylpiracetam.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/dietary/alcohol-acute
Target name:
Alcohol (Acute Consumption)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Combining the stimulant effects of phenylpiracetam with the depressant effects of alcohol can mask the feeling of intoxication, potentially leading to excessive alcohol consumption and unpredictable behavioral effects.
Actionable advice:
Alcohol is best avoided while using phenylpiracetam.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Phenylpiracetam is primarily cleared by the kidneys, and impaired renal function can lead to its accumulation in the body, increasing the risk and severity of side effects.
Actionable advice:
This is best used with caution, and dose reduction may be worth considering in those with kidney disease; it is important to talk to a physician.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
adjust_with_prescriber
Target id:
/circadian/wake
Target name:
Waking Up
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
null
Hours after target:
2
Description:
Taking phenylpiracetam in the morning aligns its stimulant and cognitive-enhancing effects with the body's natural wakefulness cycle, maximizing benefits and minimizing sleep disruption.
Actionable advice:
A daily dose is best taken within two hours of waking up for optimal effect.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/condition/hepatic-impairment
Target name:
Hepatic Impairment
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
While not extensively metabolized by the liver, severe hepatic impairment could alter drug disposition, so caution is warranted.
Actionable advice:
Consulting a physician before use may help for those with significant liver disease.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none